Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Why are malnutrition deaths soaring in America? - 2Tesla Germany Registrations Quadruple to 9,252 Vehicles in Best March Ever
- 3Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- 4Make Your Fantasy Closet: 10 Immortal Design Fundamentals
- 5How stripping diversity, equity and inclusion from health care may make Americans sicker
- How Would You Like to Deal with Your Funds?
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- The Rhythms of the Street: Shipping's Tune in the Economy's Symphony
- Figure out How to Use Your Nursing Abilities for Better Compensation
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Syria rejects forced deportations from Germany amid migration debate
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
- Etymological Experiences on the Wireless transmissions: A Survey of \Learning in a hurry\ Language Web recording
- FDA updates risk classification for voluntary shredded cheese recall
